Thalassemia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:707786
Who is this for?
Show terms as
1FDA treatments18Active trials48Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

CorrectSequence Therapeutics Co., Ltd — PHASE2

TrialNOT YET RECRUITING
Feb 2026Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients

Rongrong Liu — PHASE2

TrialRECRUITING
Sep 2025YOLT-204 in Patients With Hemoglobinopathies

Guangzhou Women and Children's Medical Center — EARLY_PHASE1

TrialNOT YET RECRUITING
Apr 2025Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia Major

Rawan Mohammed Khairy Mostafa Elsawy — NA

TrialRECRUITING
Jan 2025A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Novo Nordisk A/S — PHASE3

TrialRECRUITING
Dec 2024Thalassaemia Severity

Assiut University

TrialNOT YET RECRUITING
Dec 2024Long-term Follow-up Study of BRL-101 for TDT

Bioray Laboratories

TrialNOT YET RECRUITING
Dec 2024Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia

Institute of Hematology & Blood Diseases Hospital, China — NA

TrialRECRUITING
Oct 2024Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

Rongrong Liu — PHASE2

TrialRECRUITING
Sep 2024Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT

Haikou Affiliated Hospital of Central South University Xiangya School of Medicine

TrialENROLLING BY INVITATION

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Zynteglo

BETIBEGLOGENE AUTOTEMCEL· Genetix Biotherapeutics Inc.

ZYNTEGLO is indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions.

Clinical Trials

18 recruitingView all trials with filters →
Phase 31 trial
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Phase 3
Actively Recruiting
PI: Clinical Transparency (dept. 2834) (Novo Nordisk A/S) · Sites: Birmingham, Alabama; Phoenix, Arizona +101 more · Age: 299 yrs
Phase 24 trials
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Phase 2
Actively Recruiting
· Sites: Shenzhen, Guangdong; Baise City, Guangxi +6 more · Age: 1875 yrs
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Phase 2
Actively Recruiting
PI: Yusha Zhu, MD, PhD (Kind Pharmaceuticals LLC) · Sites: Guangzhou, Guangdong; Maoming, Guangdong +3 more · Age: 1865 yrs
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
Phase 2
Active
PI: Medical Affairs (Agios Pharmaceuticals, Inc.) · Sites: Oakland, California; Boston, Massachusetts +2 more · Age: 1899 yrs
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Phase 2
Actively Recruiting
· Sites: Maoming, Guangdong; Liuchow, Guangxi +3 more · Age: 320 yrs
Phase 12 trials
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
Phase 1
Actively Recruiting
PI: Chao Liu, PHD (Shenzhen Hemogen) · Sites: Guangxi; Shenzhen +1 more · Age: 635 yrs
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants
Phase 1
Actively Recruiting
· Sites: Nanning, Guangxi · Age: 535 yrs
N/A4 trials
Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia Major
N/A
Actively Recruiting
· Sites: Zagazig · Age: 610 yrs
Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
N/A
Actively Recruiting
· Sites: Tianjin, Tianjin Municipality · Age: 018 yrs
Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells
N/A
Actively Recruiting
PI: Jun Shi, PhD (Institute of Hematology & Blood Diseases Hospital,) · Sites: Tianjin, Tianjin Municipality · Age: 335 yrs
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
N/A
Actively Recruiting
PI: Sujiang Zhang, M.D. (Ruijin Hospital, Shanghai, China) · Sites: Shanghai · Age: 635 yrs
Other5 trials
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease
Active
PI: Lori C. Jordan, PhD, MD (Vanderbilt University Medical Center) · Sites: Birmingham, Alabama; St Louis, Missouri +2 more · Age: 1899 yrs
Study to Evaluate the Long- Term Safety and Efficacy of Luspatercept in Subjects Who Received at Least One Dose of Luspatercept in the Compassionate Use Phase
Active
PI: RAFFAELLA ORIGA (UNIVERSITA' DI CAGLIARI) · Sites: Cagliari, CA · Age: 1899 yrs
Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT
Enrolling by Invitation
PI: Xiaoyang Yang, MD (Department of Hematology, Haikou People's Hospital) · Sites: Haikou, Hainan · Age: 217 yrs
A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan
Active
PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Kaohsiung City; Tainan +3 more · Age: 1899 yrs
Long-term Follow-up Study of BHC001 for TDT
Actively Recruiting
PI: Xiaochen Wang, PhD (Bioray Laboratories) · Sites: Nanning, Guangxi; Changsha, Hunan · Age: 535 yrs

Specialists

Showing 25 of 48View all specialists →
XZ
Xinhua Zhang
Specialist
PI on 1 active trial1364 Thalassemia publications
YM
Yogi Chopra, MD
Specialist
PI on 1 active trial
SF
Sara Rubab, FCPS
Specialist
PI on 1 active trial
MF
Muhammad Aslam, FCPS
Specialist
PI on 1 active trial
CP
Chao Liu, PHD
Specialist
PI on 9 active trials
MM
Mitchell S Cairo, MD
HAWTHORNE, NY
Specialist
PI on 12 active trials
FP
FOOK-CHOE CHEAH, MD, MRCPCH, PhD
Specialist
PI on 1 active trial
MM
Matthew M Hsieh, M.D.
Bethesda, Maryland
Specialist

Rare Disease Specialist

PI on 4 active trials
JM
Juliano L Fernandes, MD
Specialist
PI on 1 active trial
XB
XIN YUN CHUA, BSc
Specialist
PI on 1 active trial
AP
AZRUL A HAMZAN, BSc, PhD
Specialist
PI on 1 active trial
CP
CHANG FU DEE, BSc, PhD
Specialist
PI on 1 active trial
HP
Haoquan Wu, PhD
Specialist
PI on 1 active trial
MM
Markus Schmugge Liner, MD
Specialist
PI on 1 active trial
PM
Petrign FG Töndury, MD
Specialist
PI on 1 active trial
SM
Suhag Parikh, MD
CHICAGO, IL
Specialist
PI on 1 active trial
JM
John F Tisdale, M.D.
Specialist
PI on 8 active trials
JS
Jianzhong Shentu
Specialist
PI on 1 active trial4 Thalassemia publications
AM
Ariel Koren, MD
Specialist
PI on 10 active trials1 Thalassemia publication
NM
Nirmish Shah, MD
DURHAM, NC
Specialist
PI on 3 active trials
DS
Daniela Mathov, Student
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
Zynteglo(BETIBEGLOGENE AUTOTEMCEL)Genetix Biotherapeutics Inc.

Travel Grants

No travel grants are currently matched to Thalassemia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open ThalassemiaForum →

No community posts yet. Be the first to share your experience with Thalassemia.

Start the conversation →

Latest news about Thalassemia

Disease timeline:

New recruiting trial: A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

A new clinical trial is recruiting patients for Thalassemia

New recruiting trial: Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

A new clinical trial is recruiting patients for Thalassemia

New recruiting trial: A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

A new clinical trial is recruiting patients for Thalassemia

New recruiting trial: the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

A new clinical trial is recruiting patients for Thalassemia

New recruiting trial: the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia

A new clinical trial is recruiting patients for Thalassemia

New recruiting trial: Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia

A new clinical trial is recruiting patients for Thalassemia

New recruiting trial: Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients

A new clinical trial is recruiting patients for Thalassemia

New recruiting trial: A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants

A new clinical trial is recruiting patients for Thalassemia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Thalassemia

Are there clinical trials for Thalassemia?

Yes — 18 recruiting clinical trials are currently listed for Thalassemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Thalassemia?

25 specialists and care centers treating Thalassemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Thalassemia?

1 patient support program are currently tracked on UniteRare for Thalassemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.